Study finds up to 94% of papillary thyroid cancers in the past three decades were overdiagnosed, with stable mortality rates, despite soaring detection rates.

CEO Richard Adcock said physicians could prescribe Anktiva for papillary bladder cancer if it is added to NCCN treatment guidelines. ・The company recently filed a supplemental biologics license ...

ImmunityBio’s sBLA targets BCG-unresponsive papillary NMIBC without CIS, complementing the existing U.S. approval for CIS ...

In most cases, treatments are successful in curing or controlling papillary thyroid cancer. Surgery is the main treatment option for this disease, though doctors may also recommend radiation therapy.

ImmunityBio (NasdaqGS:IBRX) has had its resubmitted supplemental Biologics License Application for ANKTIVA plus BCG in papillary non muscle invasive bladder cancer formally acknowledged by the FDA.

After matching, standardized mean differences were <0.1 for all key covariates. NAI + BCG showed improved outcomes versus other bladder sparing therapies in the d-uo cohort, including increased ...

Please provide your email address to receive an email when new articles are posted on . A microsimulation model estimated between 72% and 94% of papillary thyroid cancer cases in the U.S. were ...

ImmunityBio (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that the U.S. Food and Drug Administration (FDA) has acknowledged receipt of its supplemental Biologics License ...

Some studies suggest that people who are prone to thyroid carcinoma showed low levels of vitamin D compared to people who were not with cancer. To know what the findings of the study are, read on.